M. Vecchio

发表

Cancer Therapy : Preclinical T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo

C. Creighton, M. Ittmann, S. Ferrone, 2014 .

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

D. Schadendorf, V. Sondak, P. Ascierto, 2022, The Lancet.

Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.

D. Schadendorf, K. Flaherty, P. Ascierto, 2016 .

Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)

P. Ascierto, H. Schmidt, L. Bastholt, 2016 .

Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma

F. Mennini, A. Marcellusi, M. Vecchio, 2018, Clinical Drug Investigation.

Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)

P. Ascierto, J. Larkin, A. Arance, 2017 .

Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon

E. Simeone, P. Queirolo, M. Mandalà, 2014, Journal of chemotherapy.

Corrigendum: Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab. [Ann Oncol 27, (2016), (732-738)] doi:10.1093/annonc/mdw016.

P. Ascierto, E. Simeone, P. Queirolo, 2016 .

Cancer Therapy : Preclinical Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD 2-Specific T cells

A. Anichini, E. Yvon, M. Brenner, 2009 .

Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program

P. Ascierto, A. Testori, E. Simeone, 2014, Cancer investigation.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

A. Hauschild, P. Ascierto, J. Larkin, 2019, European journal of cancer.

Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.

P. Ascierto, E. Simeone, P. Queirolo, 2013 .

Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP).

P. Ascierto, A. Testori, P. Queirolo, 2013 .

LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

D. Schadendorf, V. Sondak, P. Ascierto, 2021, Annals of Oncology.

Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).

P. Ascierto, R. Dummer, J. Larkin, 2018 .

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

D. Schadendorf, P. Ascierto, P. Queirolo, 2021, Clinical Trials.

Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

P. Ascierto, A. Arance, M. Mandalà, 2019, Annals of Oncology.

miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators

M. Dugo, B. Vergani, M. Ferrarini, 2020, Cell Communication and Signaling.

MxA mRNA Quantification and Disability Progression in Interferon Beta-Treated Multiple Sclerosis Patients

V. Martinelli, G. Comi, L. Provinciali, 2014, PloS one.

COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM).

K. Flaherty, A. Arance, J. Grob, 2017 .

Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC).

M. Durante, P. Pedrazzoli, C. Fournier, 2023, Future oncology.

A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.

P. Ascierto, P. Queirolo, M. Mandalà, 2015 .

Risk of disease progression (PD) following discontinuation of BRAF±MEK targeted therapies for reasons other than PD in patients (pts) with metastatic or unresectable melanoma.

F. Braud, G. Randon, F. Corti, 2020 .

1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial

M. Mandalà, M. Guida, M. Maio, 2020 .

The European Ipilimumab Expanded Access Programme (EAP): Efficacy and Safety Data from the Italian Cohort of Patients with Pretreated, Advanced Melanoma

P. Ascierto, A. Testori, P. Queirolo, 2012 .

Melanoma and other skin tumors

Y. S. Kim, Su Jin Lee, J. Utikal, 2012 .

837 Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous (SC) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma

P. Queirolo, M. Sertoli, L. Gattinoni, 2003 .

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

D. Schadendorf, K. Flaherty, P. Ascierto, 2017, The Lancet. Oncology.

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.

L. Zitvogel, F. D. De Braud, S. Cosimo, 2018, Cytokine & growth factor reviews.

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

A. Hauschild, A. Testori, M. Del Vecchio, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238

P. Ascierto, J. Larkin, M. Mandalà, 2020 .

Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.

H. Gogas, J. Grob, L. Demidov, 2021 .

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.

P. Ascierto, E. Simeone, P. Queirolo, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.

P. Ascierto, A. Testori, E. Simeone, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.

P. Ascierto, E. Simeone, P. Queirolo, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

The practical use of cytology for diagnosis in dermatology

M. Del Vecchio, V. Ruocco, E. Ruocco, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.